Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
Identifieur interne : 000327 ( Main/Exploration ); précédent : 000326; suivant : 000328Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
Auteurs : Markus Bickel [Allemagne] ; Imke Wieters ; Pavel Khaykin ; Gabi Nisius ; Annette Haberl ; Christoph Stephan ; Nils Von Hentig ; Eva Herrmann ; Hans W. Doerr ; Hans R. Brodt ; Regina AllwinnSource :
- AIDS (London, England) [ 1473-5571 ] ; 2010.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Allemagne (épidémiologie), Anticorps antiviraux (sang), Facteurs de l'âge, Femelle, Grippe humaine (), Grippe humaine (épidémiologie), Humains, Mâle, Numération des lymphocytes CD4, Sous-type H1N1 du virus de la grippe A (immunologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Virion (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux, Virion.
- sang : Anticorps antiviraux.
- épidémiologie : Allemagne, Grippe humaine.
- Adulte d'âge moyen, Facteurs de l'âge, Femelle, Grippe humaine, Humains, Mâle, Numération des lymphocytes CD4, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Age Factors, Antibodies, Viral (blood), CD4 Lymphocyte Count, Female, Germany (epidemiology), HIV-1, Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male, Middle Aged, Virion (immunology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- geographic , epidemiology : Germany.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Virion.
- prevention & control : Influenza, Human.
- Age Factors, CD4 Lymphocyte Count, Female, HIV-1, Humans, Male, Middle Aged.
Abstract
To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).
DOI: 10.1097/QAD.0b013e3283398da1
PubMed: 20559034
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</title>
<author><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name>
<affiliation wicri:level="3"><nlm:affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>HIVCENTER, Frankfurt</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name>
</author>
<author><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name>
</author>
<author><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name>
</author>
<author><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name>
</author>
<author><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name>
</author>
<author><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name>
</author>
<author><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name>
</author>
<author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name>
</author>
<author><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name>
</author>
<author><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20559034</idno>
<idno type="pmid">20559034</idno>
<idno type="doi">10.1097/QAD.0b013e3283398da1</idno>
<idno type="wicri:Area/Main/Corpus">000323</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000323</idno>
<idno type="wicri:Area/Main/Curation">000323</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000323</idno>
<idno type="wicri:Area/Main/Exploration">000323</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</title>
<author><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name>
<affiliation wicri:level="3"><nlm:affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>HIVCENTER, Frankfurt</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name>
</author>
<author><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name>
</author>
<author><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name>
</author>
<author><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name>
</author>
<author><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name>
</author>
<author><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name>
</author>
<author><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name>
</author>
<author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name>
</author>
<author><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name>
</author>
<author><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name>
</author>
</analytic>
<series><title level="j">AIDS (London, England)</title>
<idno type="eISSN">1473-5571</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Antibodies, Viral (blood)</term>
<term>CD4 Lymphocyte Count</term>
<term>Female</term>
<term>Germany (epidemiology)</term>
<term>HIV-1</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Virion (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Allemagne (épidémiologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Facteurs de l'âge</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Virion (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Virion</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza Vaccines</term>
<term>Virion</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>CD4 Lymphocyte Count</term>
<term>Female</term>
<term>HIV-1</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Facteurs de l'âge</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20559034</PMID>
<DateCompleted><Year>2010</Year>
<Month>12</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>06</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>24</Volume>
<Issue>9</Issue>
<PubDate><Year>2010</Year>
<Month>Jun</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>AIDS (London, England)</Title>
<ISOAbbreviation>AIDS</ISOAbbreviation>
</Journal>
<ArticleTitle>Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</ArticleTitle>
<Pagination><MedlinePgn>F31-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e3283398da1</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">Single center diagnostic study.</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">Institutional HIV outpatient department of an urban university clinic.</AbstractText>
<AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adult HIV-1-infected individuals.</AbstractText>
<AbstractText Label="INTERVENTION" NlmCategory="METHODS">Serum samples were taken before and 21 days after vaccination.</AbstractText>
<AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bickel</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wieters</LastName>
<ForeName>Imke</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Khaykin</LastName>
<ForeName>Pavel</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nisius</LastName>
<ForeName>Gabi</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Haberl</LastName>
<ForeName>Annette</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stephan</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Von Hentig</LastName>
<ForeName>Nils</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Herrmann</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Doerr</LastName>
<ForeName>Hans W</ForeName>
<Initials>HW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brodt</LastName>
<ForeName>Hans R</ForeName>
<Initials>HR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Allwinn</LastName>
<ForeName>Regina</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01017172</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>AIDS</MedlineTA>
<NlmUniqueID>8710219</NlmUniqueID>
<ISSNLinking>0269-9370</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>AIDS. 2010 Aug 24;24(13):2142-3</RefSource>
<PMID Version="1">20679764</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>12</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20559034</ArticleId>
<ArticleId IdType="doi">10.1097/QAD.0b013e3283398da1</ArticleId>
<ArticleId IdType="pii">00002030-201006010-00001</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>District de Darmstadt</li>
<li>Hesse (Land)</li>
</region>
<settlement><li>Francfort-sur-le-Main</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name>
<name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name>
<name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name>
<name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name>
<name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name>
<name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name>
<name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name>
<name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name>
<name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name>
<name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name>
</noCountry>
<country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=ExplorPubmed/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000327 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000327 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= ExplorPubmed |flux= Main |étape= Exploration |type= RBID |clé= pubmed:20559034 |texte= Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20559034" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ExplorPubmed
This area was generated with Dilib version V0.6.35. |